The compound at the base of this drug is named Belantamab madofotin-blmf, an antibody–drug conjugate directed against the B-cell maturation antigen (BCMA); it is indicated for adult patients with multiple myeloma. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.